Bio-Rad Laboratories, Inc. is a multinational life science and clinical diagnostics company that develops, manufactures, and markets instruments, systems, reagents, and consumables. The company operates in two segments: Life Science and Clinical Diagnostics. The Life Science segment provides products for separating, purifying, characterizing, and quantifying biological materials such as cells, proteins, and nucleic acids, serving research, biopharmaceutical manufacturing, quality control, food safety, and science education markets. The Clinical Diagnostics segment designs and supplies diagnostic test systems, informatics solutions, test kits, and quality controls for in vitro diagnostics (IVD) applications in clinical laboratories. Bio-Rad serves customers worldwide, including universities, medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, hospital laboratories, diagnostic reference laboratories, and physician office laboratories. The company maintains direct operations in multiple countries and utilizes distributors and agents in international markets. Its product portfolio includes thousands of life science products and supports more than 300 clinical diagnostic tests. Bio-Rad competes with major industry players such as Thermo Fisher Scientific, Danaher, and Roche, focusing on differentiated capabilities, technical support, and comprehensive solutions.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage bio-rad.com
Sector Healthcare IR page investors.bio-rad.com
Tags
in vitro diagnostics, life science research, biopharmaceutical manufacturing, clinical laboratories, protein purification, nucleic acid analysis, food safety testing, diagnostic test kits, laboratory instruments, reagents, consumables, informatics solutions
Press page —

Metrics

Valuation  
Market cap $ 10.177B
Market cap (USD) $ 10.177B
P/E 9.96
PEG —
P/BV 1.34
P/S 3.93
P/OCF 21.74
P/FCF 30.92
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.8%
ROI 8.8%
ROIC 0.42%
Profit margin 29.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 10.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 2.583B 2.567B 2.671B 2.802B 2.923B 2.546B 2.312B 2.289B 2.16B 2.068B 2.019B 2.175B 2.133B 2.069B 2.074B 1.927B 1.784B 1.764B 1.461B 1.274B 1.181B 1.09B 1.003B 892.72M 817.509M 725.884M
Net profit 759.9M -1.844B -637.324M -3.628B 4.246B 3.806B 1.759B 365.614M 122.249M 28.125M 113.093M 88.845M 77.79M 163.778M 178.223M 185.49M 144.62M 89.51M 92.994M 103.263M 81.553M 68.242M 76.171M 67.863M 44.179M 31.1M
Free cash flow 374.6M 289.6M 218.263M 81.665M 535.718M 476.38M 359.365M 155.669M -7.447M 74.997M 74.21M 152.313M 62.478M 126.481M 156.928M 138.646M 258.279M 106.562M 130.985M 65.242M 72.229M 62.6M 58.637M 62.611M 56.267M -7.159M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 302.99 328.51 322.89 420.49 755.57 582.94 370.03 232.22 238.67 182.28 138.66 120.56 123.61 105.05 96.02 103.8 96.44 — 80.29 71.29 56.9 56.9 — — — —
Price performance 12m -0.08 0.02 -0.23 -0.44 0.3 0.58 0.59 -0.03 0.31 0.31 0.15 -0.02 0.18 0.09 -0.07 0.08 — — 0.13 0.25 0 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 372M 465M 392M 393M 419M 424M 495M 489M 453M 461M
↳ YoY growth -4.9% +24.8% -15.6% +0.1% +6.8% +1.0% +16.8% -1.1% -7.5% +1.8%
↳ 5y CAGR -1.4% +3.1% -1.5% +0.8% +1.4% +2.6% +1.3% +4.5% +2.9% +1.9%
Borrowings, non-current (USD) 434M 435M 439M 13.6M 12.3M 10.5M 1.2B 1.2B 1.2B 1.2B
Lease liabilities (USD) — — 0.00 223M 223M 223M 201M 216M 183M 191M
Cash and deposits (USD) 456M 384M 432M 661M 662M 471M 434M 404M 488M 530M
Intangible assets (USD) 162M 174M 133M 146M 199M 254M 332M 321M 294M 174M
Right-of-use assets (USD) — — 0.00 202M 202M 205M 181M 195M 161M 170M
Net debt (borrowings + leases - cash) (USD) -22.1M 50.8M 7.37M -424M -427M -237M 964M 1.01B 895M 863M
Cash flow detail
Operating cash flow (USD) 216M 104M 285M 458M 575M 657M 194M 375M 455M 532M
Purchases of property, plant and equipment (USD) -141M -111M -130M -98.5M -98.9M -121M -113M -157M -166M -158M
Purchases of intangible assets (USD) -135,000 -3.8M -3,000 — — — — — — —
Change in receivables (cash effect) (USD) 12.5M -64.1M 59.7M 1.6M -15M -20.4M -87.4M 11.4M 16.2M 19.6M
Change in inventories (cash effect) (USD) -57.1M -47.7M -12.9M 24.2M -52.1M 46.1M -159M -46.3M 8.5M 68.9M
Share buybacks (cash effect) (USD) 0.00 -2.92M -48.9M -28M -100M -50M -216M -429M -204M -296M
Interest paid (cash effect) (USD) -21.3M -21.1M -22.7M -22.3M -21.6M -2.25M -24.4M -47.5M -46.5M -46.6M
Income taxes paid (cash effect) (USD) -38.4M -52.1M -62.4M -45.1M -65.2M -135M -158M -130M -99.4M -61.6M
Share-based compensation (USD) 19.7M 23.4M 27.8M 35.6M 41.6M 51.2M 60.9M 61.3M 62.3M 58M
Operating cash flow before change in receivables (USD) 204M 168M 226M 456M 590M 677M 282M 364M 439M 513M
Free cash flow (OCF - PPE - intangibles) (USD) 74.9M -11.2M 156M 359M 476M 536M 81.7M 218M 290M 375M
Income detail
Research and development expense (USD) 206M 250M 199M 203M 227M 272M 257M 247M 296M 276M
↳ 5y CAGR +2.0% +3.2% -1.1% -1.7% +3.3% +5.7% +0.5% +4.4% +7.9% +4.0%
Total comprehensive income (USD) 63.8M 443M 259M 1.72B 4.18B 3.79B -3.92B -507M -2.05B 1.11B
Comprehensive income to owners (USD) 63.8M 443M 259M 1.72B 4.18B 3.79B -3.92B -507M -2.05B 1.11B
Reported Apr 16, 2018 Apr 16, 2018 May 10, 2019 Mar 2, 2020 Feb 16, 2021 Feb 11, 2022 Feb 17, 2023 Feb 16, 2024 Feb 14, 2025 Feb 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Bio-Rad Reports Third-Quarter 2026 Financial Results Bull 2 Bear 0 Results

November 4, 2026

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026.

Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments. Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives. The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook.”

| Financial Results Highlights | | |

| | | |

| (In millions, except per share data and percentages) | | |

| | | |

| GAAP Results |

| | Q3 2026 | Q3 2025 |

| Net sales | $ | 656.4 | | $ | 653.0 | |

| Gross margin | | 50.1 | % | | 52.6 | % |

| Income (loss) from operations | $ | (49.7 | ) | $ | 65.3 | |

| Operating margin | | (7.6 | )% | | 10.0 | % |

| Net income (loss) | $ | 458.6 | | $ | (341.9 | ) |

| Income (loss) per diluted share | $ | 17.02 | | $ | (12.70 | ) |

| Net cash from operations | $ | 96.4 | | $ | 120.9 | |

| |

| Non-GAAP Results |

| | Q3 2026 | Q3 2025 |

| Net sales | $ | 656.4 | | $ | 653.0 | |

| Gross margin | | 54.5 | % | | 53.5 | % |

| Income from operations | $ | 83.7 | | $ | 77.0 | |

| Operating margin | | 12.8 | % | | 11.8 | % |

| Net income | $ | 71.5 | | $ | 60.8 | |

| Income per diluted share | $ | 2.65 | | $ | 2.26 | |

| Free cash flow | $ | 65.2 | | $ | 89.2 | |

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Reporting”. A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Third-Quarter 2026 Results

Third-quarter 2026 total net sales were $656.4 million compared to $653.0 million reported for the third quarter of 2025, an increase of 0.5%. On a currency-neutral basis, sales increased 0.7 percent compared to the same period in 2025, driven by higher sales in Clinical Diagnostics segment.

Life Science segment net sales for the third quarter were $254.6 million, a decrease of 2.8 percent compared to the same period in 2025. On a currency-neutral basis, Life Science segment sales decreased 2.4 percent compared to the same period in 2025. The currency-neutral year-over-year sales decrease was primarily driven by lower process chromatography sales and ongoing challenges in the academic research market partially offset by increased Droplet Digital™ PCR sales.

Clinical Diagnostics segment net sales for the third quarter were $401.8 million, an increase of 2.7 percent compared to the same period in 2025. On a currency-neutral basis, Clinical Diagnostics segment sales increased 2.8 percent compared to the same period in 2025. The currency-neutral year-over-year sales increase was primarily driven by growth in quality systems and diabetes products.

During the third quarter of 2026, the Company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net income of $458.6 million, or $17.02 per share, on a diluted basis, compared to a net loss of $(341.9) million, or $(12.70) per share, on a diluted basis, reported for the same period in 2025.

The effective tax rate for the third quarter of 2026 was 14.9 percent, compared to 20.7 percent for the same period in 2025. The effective tax rate reported in these periods was primarily affected by the change in fair market value of our equity securities, shifts in the geographical mix of earnings, and release of valuation allowance established with respect to our deferred tax assets.

The non-GAAP effective tax rate for the third quarter of 2026 was 21.4 percent, compared to 26.7 percent for the same period in 2025. The lower rate in 2026 was driven by geographical mix of earnings.

Full-Year 2026 Financial Outlook

For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.

Conference Call and Webcast

Management will discuss the Company’s third quarter 2026 results and financial outlook in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) on November 4, 2026. To participate, dial (800) 715-9871 within the U.S., or (+1) (646) 307-1963 from outside the U.S., and provide access code: 9562470.

A live webcast of the conference call will also be available in the “Investor Relations” section of the Company’s website under “Events & Presentations” at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

BIO-RAD and Droplet Digital PCR are trademarks of Bio-Rad Laboratories, Inc.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,100 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; our progress giving us confidence in our 2026 outlook; and for the full-year 2026: continuing to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "expect,” "estimate," "continue," “remain,” "believe," "anticipate," “target,” "will," "project," "assume," “plan,” "may," "intend," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations; global economic and geopolitical conditions; tariffs or other trade barriers; reductions in government funding or capital spending of our customers; the uncertain pace of the biopharma sector’s recovery; international legal and regulatory risks; our ability to develop and market new or improved products; our ability to compete effectively; foreign currency exchange fluctuations; our ability to integrate acquired companies, products or technologies into our company successfully; supply chain issues; product quality and liability issues; changes in the healthcare industry; and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

| BIO-RAD LABORATORIES, INC. |

| Condensed Consolidated Statements of Income (Loss) |

| (In millions, except number of shares, which are reflected in thousands, and per share data) |

| (Unaudited) |

| | | | | | | | |

| | Three Months Ended | | Nine Months Ended |

| | September 30, | | September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Net sales | $ | 656.4 | | | $ | 653.0 | | | $ | 1,899.5 | | | $ | 1,890.0 | |

| Cost of goods sold | | 327.8 | | | | 309.6 | | | | 915.7 | | | | 895.3 | |

| Gross profit | | 328.6 | | | | 343.4 | | | | 983.8 | | | | 994.7 | |

| Selling, general and administrative expense | | 257.1 | | | | 206.8 | | | | 681.5 | | | | 623.3 | |

| Research and development expense | | 71.4 | | | | 71.3 | | | | 195.5 | | | | 205.3 | |

| Impairment of purchased intangibles | | 49.8 | | | | — | | | | 49.8 | | | | — | |

| Income (loss) from operations | | (49.7 | ) | | | 65.3 | | | | 57.0 | | | | 166.1 | |

| Interest expense | | 12.3 | | | | 12.3 | | | | 36.7 | | | | 36.9 | |

| Foreign currency exchange gains, net | | (2.1 | ) | | | (2.9 | ) | | | (4.7 | ) | | | (4.5 | ) |

| (Gains) losses from change in fair market value of equity securities and loan receivable | | (588.2 | ) | | | 495.3 | | | | (308.0 | ) | | | 129.1 | |

| Other income, net | | (10.4 | ) | | | (8.3 | ) | | | (58.0 | ) | | | (61.7 | ) |

| Income (loss) before income taxes | | 538.7 | | | | (431.1 | ) | | | 391.0 | | | | 66.3 | |

| (Provision for) benefit from income taxes | | (80.1 | ) | | | 89.2 | | | | (88.1 | ) | | | (26.4 | ) |

| Net income (loss) | $ | 458.6 | | | $ | (341.9 | ) | | $ | 302.9 | | | $ | 39.9 | |

| | | | | | | | |

| Basic earnings (loss) per share: | | | | | | | |

| Net income (loss) per basic share | $ | 17.13 | | | $ | (12.70 | ) | | $ | 11.29 | | | $ | 1.46 | |

| Weighted average common shares - basic | | 26,780 | | | | 26,923 | | | | 26,827 | | | | 27,359 | |

| | | | | | | | |

| Diluted earnings (loss) per share: | | | | | | | |

| Net income (loss) per diluted share | $ | 17.02 | | | $ | (12.70 | ) | | $ | 11.25 | | | $ | 1.46 | |

| Weighted average common shares - diluted | | 26,945 | | | | 26,923 | | | | 26,923 | | | | 27,369 | |

| | | | | | | | |

| Note: As a result of the net loss for the three months ended September 30, 2025, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effect was anti-dilutive. |

| |

| BIO-RAD LABORATORIES, INC. |

| Condensed Consolidated Balance Sheets |

| (In millions) |

| | | | |

| | September 30, 2026 | | December 31, 2025 |

| | (Unaudited) | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 465.3 | | $ | 529.8 |

| Short-term investments | | 1,199.0 | | | 1,010.9 |

| Accounts receivable, net | | 422.6 | | | 460.6 |

| Inventories, net | | 783.9 | | | 740.7 |

| Other current assets | | 207.8 | | | 164.2 |

| Total current assets | | 3,078.6 | | | 2,906.2 |

| | | | |

| Property, plant and equipment, net | | 505.7 | | | 539.9 |

| Operating lease right-of-use assets | | 147.1 | | | 170.0 |

| Goodwill, net | | 573.0 | | | 579.8 |

| Purchased intangibles, net | | 104.4 | | | 174.3 |

| Other investments | | 6,273.2 | | | 6,103.6 |

| Other assets | | 101.1 | | | 102.7 |

| Total assets | $ | 10,783.1 | | $ | 10,576.5 |

| | | | |

| Current liabilities: | | | |

| Accounts payable, accrued payroll and employee benefits | $ | 343.8 | | $ | 301.3 |

| Current maturities of long-term debt and notes payable | | 400.9 | | | 1.3 |

| Income and other taxes payable | | 37.8 | | | 36.6 |

| Other current liabilities | | 186.6 | | | 177.8 |

| Total current liabilities | | 969.1 | | | 517.0 |

| | | | |

| Long-term debt, net of current maturities | | 803.1 | | | 1,201.7 |

| Other long-term liabilities | | 1,407.9 | | | 1,404.2 |

| Total liabilities | | 3,180.1 | | | 3,122.9 |

| | | | |

| Total stockholders’ equity | | 7,603.0 | | | 7,453.6 |

| Total liabilities and stockholders’ equity | $ | 10,783.1 | | $ | 10,576.5 |

| | | | |

| BIO-RAD LABORATORIES, INC. |

| Condensed Consolidated Statements of Cash Flows |

| (In millions) |

| (Unaudited) |

| | Nine Months Ended |

| | September 30, |

| | | 2026 | | | | 2025 | |

| Cash flows from operating activities: | | | |

| Cash received from customers | $ | 1,915.9 | | | $ | 1,958.7 | |

| Cash paid to suppliers and employees | | (1,607.8 | ) | | | (1,511.4 | ) |

| Interest paid, net | | (45.7 | ) | | | (45.5 | ) |

| Income tax payments, net | | (40.4 | ) | | | (54.3 | ) |

| Other operating activities | | 81.2 | | | | 19.8 | |

| Net cash provided by operating activities | | 303.2 | | | | 367.3 | |

| Cash flows from investing activities: | | | |

| (Payments for) proceeds from acquisitions, net of cash received | | 1.1 | | | | (218.5 | ) |

| Payments for purchases of marketable securities and investments | | (677.7 | ) | | | (530.5 | ) |

| Proceeds from sales and maturities of marketable securities and investments | | 464.0 | | | | 705.2 | |

| Payments for purchases of property, plant and equipment, net of proceeds from dispositions | | (93.2 | ) | | | (111.7 | ) |

| Net cash used in investing activities | | (305.8 | ) | | | (155.5 | ) |

| Cash flows from financing activities: | | | |

| Payments on long-term debt | | (0.4 | ) | | | (0.3 | ) |

| Payments for purchases of treasury stock | | (79.3 | ) | | | (295.5 | ) |

| Other financing activities | | 6.5 | | | | 9.3 | |

| Net cash used in financing activities | | (73.2 | ) | | | (286.5 | ) |

| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | | 10.7 | | | | (16.9 | ) |

| Net decrease in cash, cash equivalents and restricted cash | | (65.1 | ) | | | (91.6 | ) |

| Cash, cash equivalents and restricted cash at beginning of period | | 532.2 | | | | 489.8 | |

| Cash, cash equivalents and restricted cash at end of period | $ | 467.1 | | | $ | 398.2 | |

| | | | |

| Reconciliation of net income to net cash provided by operating activities: | | | |

| Net income | $ | 302.9 | | | $ | 39.9 | |

| Adjustments to reconcile net income to net cash provided by operating activities: | | | |

| Depreciation and amortization | | 123.2 | | | | 122.9 | |

| Impairment of purchased intangibles | | 49.8 | | | | — | |

| Reduction in the carrying amount of right-of-use assets | | 28.4 | | | | 30.1 | |

| Share-based compensation | | 45.0 | | | | 42.1 | |

| (Gains) losses from change in fair market value of equity securities and loan receivable | | (308.0 | ) | | | 129.1 | |

| Changes in working capital | | (35.0 | ) | | | 4.5 | |

| Changes in deferred income taxes | | 60.6 | | | | (19.7 | ) |

| Other | | 36.3 | | | | 18.4 | |

| Net cash provided by operating activities | $ | 303.2 | | | $ | 367.3 | |

| | | | |

| Use of Non-GAAP Reporting |

| | | | | | | | | | | | | | | | |

| This press release includes GAAP financial measures as well as non-GAAP financial measures, which are not meant to be considered in isolation or as a substitute for comparable GAAP measures. We present certain non-GAAP financial measures to evaluate business performance, guide operating decisions, support forecasting and planning, and determine compensation. These measures exclude items outside normal operations, those difficult to forecast, isolated gains and losses not expected to recur predictably, related tax provisions or benefits, and significant discrete tax events. We believe these disclosures provide useful supplemental information that, while not a substitute for GAAP, enhance transparency, assist in evaluating operating results and future prospects in the same manner as management, and facilitate comparisons across periods and with peer companies. |

| | | | | | | | | | | | | | | | |

| BIO-RAD LABORATORIES, INC. |

| Reconciliation of GAAP financial measures to non-GAAP financial measures |

| (In millions, except number of shares, which are reflected in thousands, and per share data) |

| (Unaudited) |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| | Three Months Ended | | | | Three Months Ended | | | | Nine Months Ended | | | | Nine Months Ended | | |

| | September 30, 2026 | | % of revenue | | September 30, 2025 | | % of revenue | | September 30, 2026 | | % of revenue | | September 30, 2025 | | % of revenue |

| | | | | | | | | | | | | | | | |

| GAAP cost of goods sold | $ | 327.8 | | | | | $ | 309.6 | | | | | $ | 915.7 | | | | | $ | 895.3 | | | |

| Amortization of purchased intangibles | | (4.5 | ) | | | | | (6.6 | ) | | | | | (15.1 | ) | | | | | (15.5 | ) | | |

| Restructuring benefits (costs) | | (24.7 | ) | | | | | 0.6 | | | | | | (24.5 | ) | | | | | (4.1 | ) | | |

| Non-GAAP cost of goods sold | $ | 298.6 | | | | | $ | 303.6 | | | | | $ | 876.1 | | | | | $ | 875.7 | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP gross profit | $ | 328.6 | | | 50.1 | % | | $ | 343.4 | | | 52.6 | % | | $ | 983.8 | | | 51.8 | % | | $ | 994.7 | | | 52.6 | % |

| Amortization of purchased intangibles | | 4.5 | | | | | | 6.6 | | | | | | 15.1 | | | | | | 15.5 | | | |

| Restructuring (benefits) costs | | 24.7 | | | | | | (0.6 | ) | | | | | 24.5 | | | | | | 4.1 | | | |

| Non-GAAP gross profit | $ | 357.8 | | | 54.5 | % | | $ | 349.4 | | | 53.5 | % | | $ | 1,023.4 | | | 53.9 | % | | $ | 1,014.3 | | | 53.7 | % |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP selling, general and administrative expense | $ | 257.1 | | | | | $ | 206.8 | | | | | $ | 681.5 | | | | | $ | 623.3 | | | |

| Amortization of purchased intangibles | | (0.5 | ) | | | | | (0.7 | ) | | | | | (1.8 | ) | | | | | (2.0 | ) | | |

| Acquisition related benefits (costs) | | — | | | | | | (0.6 | ) | | | | | (0.2 | ) | | | | | (3.4 | ) | | |

| Restructuring benefits (costs) | | (41.4 | ) | | | | | (2.4 | ) | | | | | (42.2 | ) | | | | | (20.3 | ) | | |

| European Union’s IVDR | | (1.1 | ) | | | | | (0.9 | ) | | | | | (3.4 | ) | | | | | (3.1 | ) | | |

| Non-GAAP selling, general and administrative expense | $ | 214.1 | | | | | $ | 202.2 | | | | | $ | 633.9 | | | | | $ | 594.5 | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP research and development expense | $ | 71.4 | | | | | $ | 71.3 | | | | | $ | 195.5 | | | | | $ | 205.3 | | | |

| Acquisition related benefits (costs) | | (0.3 | ) | | | | | (0.4 | ) | | | | | (0.7 | ) | | | | | (0.4 | ) | | |

| Restructuring benefits (costs) | | (11.1 | ) | | | | | (0.7 | ) | | | | | (9.4 | ) | | | | | (13.7 | ) | | |

| Non-GAAP research and development expense | $ | 60.0 | | | | | $ | 70.2 | | | | | $ | 185.4 | | | | | $ | 191.2 | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP impairment of purchased intangibles | $ | 49.8 | | | | | | — | | | | | $ | 49.8 | | | | | | — | | | |

| Impairment of purchased intangibles | | (49.8 | ) | | | | | — | | | | | | (49.8 | ) | | | | | — | | | |

| Non-GAAP impairment of purchased intangibles | | — | | | | | | — | | | | | | — | | | | | | — | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP income (loss) from operations | $ | (49.7 | ) | | (7.6 | %) | | $ | 65.3 | | | 10.0 | % | | $ | 57.0 | | | 3.0 | % | | $ | 166.1 | | | 8.8 | % |

| Amortization of purchased intangibles | | 5.0 | | | | | | 7.3 | | | | | | 16.9 | | | | | | 17.5 | | | |

| Acquisition related (benefits) costs | | 0.3 | | | | | | 1.0 | | | | | | 0.9 | | | | | | 3.8 | | | |

| Restructuring (benefits) costs | | 77.2 | | | | | | 2.5 | | | | | | 76.1 | | | | | | 38.1 | | | |

| European Union’s IVDR | | 1.1 | | | | | | 0.9 | | | | | | 3.4 | | | | | | 3.1 | | | |

| Impairment of purchased intangibles | | 49.8 | | | | | | — | | | | | | 49.8 | | | | | | — | | | |

| Non-GAAP income from operations | $ | 83.7 | | | 12.8 | % | | $ | 77.0 | | | 11.8 | % | | $ | 204.1 | | | 10.7 | % | | $ | 228.6 | | | 12.1 | % |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP (gains) losses from change in fair market value of equity securities and loan receivable | $ | (588.2 | ) | | | | $ | 495.3 | | | | | $ | (308.0 | ) | | | | $ | 129.1 | | | |

| Gains (losses) from change in fair market value of equity securities and loan receivable | | 588.2 | | | | | | (495.3 | ) | | | | | 308.0 | | | | | | (129.1 | ) | | |

| Non-GAAP (gains) losses from change in fair market value of equity securities and loan receivable | | — | | | | | | — | | | | | | — | | | | | | — | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP other income, net | $ | (10.4 | ) | | | | $ | (8.3 | ) | | | | $ | (58.0 | ) | | | | $ | (61.7 | ) | | |

| Gains (losses) on equity-method investments | | (7.1 | ) | | | | | (7.0 | ) | | | | | (12.6 | ) | | | | | (6.2 | ) | | |

| Non-GAAP other income, net | $ | (17.5 | ) | | | | $ | (15.3 | ) | | | | $ | (70.6 | ) | | | | $ | (67.9 | ) | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP income (loss) before income taxes | $ | 538.7 | | | | | $ | (431.1 | ) | | | | $ | 391.0 | | | | | $ | 66.3 | | | |

| Amortization of purchased intangibles | | 5.0 | | | | | | 7.3 | | | | | | 16.9 | | | | | | 17.5 | | | |

| Acquisition related (benefits) costs | | 0.3 | | | | | | 1.0 | | | | | | 0.9 | | | | | | 3.8 | | | |

| Restructuring (benefits) costs | | 77.2 | | | | | | 2.5 | | | | | | 76.1 | | | | | | 38.1 | | | |

| European Union’s IVDR | | 1.1 | | | | | | 0.9 | | | | | | 3.4 | | | | | | 3.1 | | | |

| Impairment of purchased intangibles | | 49.8 | | | | | | — | | | | | | 49.8 | | | | | | — | | | |

| (Gains) losses from change in fair market value of equity securities and loan receivable | | (588.2 | ) | | | | | 495.3 | | | | | | (308.0 | ) | | | | | 129.1 | | | |

| (Gains) losses on equity-method investments | | 7.1 | | | | | | 7.0 | | | | | | 12.6 | | | | | | 6.2 | | | |

| Non-GAAP income before income taxes | $ | 91.0 | | | | | $ | 82.9 | | | | | $ | 242.7 | | | | | $ | 264.1 | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP (provision for) benefit from income taxes | $ | (80.1 | ) | | | | $ | 89.2 | | | | | $ | (88.1 | ) | | | | $ | (26.4 | ) | | |

| Income tax effect of non-GAAP adjustments | | 60.6 | | | | | | (111.3 | ) | | | | | 38.0 | | | | | | (34.9 | ) | | |

| Non-GAAP provision for income taxes | $ | (19.5 | ) | | | | $ | (22.1 | ) | | | | $ | (50.1 | ) | | | | $ | (61.3 | ) | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP net income (loss) | $ | 458.6 | | | 69.9 | % | | $ | (341.9 | ) | | (52.4 | %) | | $ | 302.9 | | | 15.9 | % | | $ | 39.9 | | | 2.1 | % |

| Amortization of purchased intangibles | | 5.0 | | | | | | 7.3 | | | | | | 16.9 | | | | | | 17.5 | | | |

| Acquisition related (benefits) costs | | 0.3 | | | | | | 1.0 | | | | | | 0.9 | | | | | | 3.8 | | | |

| Restructuring (benefits) costs | | 77.2 | | | | | | 2.5 | | | | | | 76.1 | | | | | | 38.1 | | | |

| European Union’s IVDR | | 1.1 | | | | | | 0.9 | | | | | | 3.4 | | | | | | 3.1 | | | |

| Impairment of purchased intangibles | | 49.8 | | | | | | — | | | | | | 49.8 | | | | | | — | | | |

| (Gains) losses from change in fair market value of equity securities and loan receivable | | (588.2 | ) | | | | | 495.3 | | | | | | (308.0 | ) | | | | | 129.1 | | | |

| (Gains) losses on equity-method investments | | 7.1 | | | | | | 7.0 | | | | | | 12.6 | | | | | | 6.2 | | | |

| Income tax effect of non-GAAP adjustments | | 60.6 | | | | | | (111.3 | ) | | | | | 38.0 | | | | | | (34.9 | ) | | |

| Non-GAAP net income | $ | 71.5 | | | 10.9 | % | | $ | 60.8 | | | 9.3 | % | | $ | 192.6 | | | 10.1 | % | | $ | 202.8 | | | 10.7 | % |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP diluted income (loss) per share | $ | 17.02 | | | | | $ | (12.70 | ) | | | | $ | 11.25 | | | | | $ | 1.46 | | | |

| Amortization of purchased intangibles | | 0.19 | | | | | | 0.27 | | | | | | 0.63 | | | | | | 0.64 | | | |

| Acquisition related (benefits) costs | | 0.01 | | | | | | 0.04 | | | | | | 0.03 | | | | | | 0.14 | | | |

| Restructuring (benefits) costs | | 2.87 | | | | | | 0.09 | | | | | | 2.83 | | | | | | 1.39 | | | |

| European Union’s IVDR | | 0.04 | | | | | | 0.03 | | | | | | 0.13 | | | | | | 0.11 | | | |

| Impairment of purchased intangibles | | 1.85 | | | | | | — | | | | | | 1.85 | | | | | | — | | | |

| (Gains) losses from change in fair market value of equity securities and loan receivable | | (21.83 | ) | | | | | 18.38 | | | | | | (11.44 | ) | | | | | 4.72 | | | |

| (Gains) losses on equity-method investments | | 0.26 | | | | | | 0.26 | | | | | | 0.47 | | | | | | 0.23 | | | |

| Income tax effect of non-GAAP adjustments | | 2.24 | | | | | | (4.12 | ) | | | | | 1.40 | | | | | | (1.28 | ) | | |

| Add back anti-dilutive shares | | — | | | | | | 0.01 | | | | | | — | | | | | | — | | | |

| Non-GAAP diluted income per share | $ | 2.65 | | | | | $ | 2.26 | | | | | $ | 7.15 | | | | | $ | 7.41 | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| GAAP diluted weighted average shares used in per share calculation | | 26,945 | | | | | | 26,923 | | | | | | 26,923 | | | | | | 27,369 | | | |

| Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive | | — | | | | | | 27 | | | | | | — | | | | | | — | | | |

| Non-GAAP diluted weighted average shares used in per share calculation | | 26,945 | | | | | | 26,950 | | | | | | 26,923 | | | | | | 27,369 | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| | Three Months Ended | | | | Three Months Ended | | | | Nine Months Ended | | | | Nine Months Ended | | |

| | September 30, 2026 | | | | September 30, 2025 | | | | September 30, 2026 | | | | September 30, 2025 | | |

| | | | | | | | | | | | | | | | |

| Reconciliation of free cash flow: | | | | | | | | | | | | | | | |

| GAAP net cash provided by operating activities | $ | 96.4 | | | | | $ | 120.9 | | | | | $ | 303.2 | | | | | $ | 367.3 | | | |

| Payments for property, plant, and equipment | | (31.2 | ) | | | | | (31.7 | ) | | | | | (93.2 | ) | | | | | (111.8 | ) | | |

| Free cash flow | $ | 65.2 | | | | | $ | 89.2 | | | | | $ | 210.0 | | | | | $ | 255.5 | | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| Currency-Neutral Revenue | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| Life Science segment revenue | | | | | | | | | | | | | | | |

| Revenue growth (decline), reported | | (2.8 | %) | | | | | 0.3 | % | | | | | (2.4 | %) | | | | | — | | | |

| Change due to foreign exchange | | 0.4 | % | | | | | (1.8 | %) | | | | | (1.5 | %) | | | | | (0.3 | %) | | |

| Currency-neutral revenue growth (decline) | | (2.4 | %) | | | | | (1.5 | %) | | | | | (3.9 | %) | | | | | (0.3 | %) | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| Clinical Diagnostics segment revenue | | | | | | | | | | | | | | | |

| Revenue growth (decline), reported | | 2.7 | % | | | | | 0.6 | % | | | | | 2.4 | % | | | | | (0.8 | %) | | |

| Change due to foreign exchange | | 0.1 | % | | | | | (2.4 | %) | | | | | (2.7 | %) | | | | | (0.1 | %) | | |

| Currency-neutral revenue growth (decline) | | 2.8 | % | | | | | (1.8 | %) | | | | | (0.3 | %) | | | | | (0.9 | %) | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| Total revenue | | | | | | | | | | | | | | | |

| Revenue growth (decline), reported | | 0.5 | % | | | | | 0.5 | % | | | | | 0.5 | % | | | | | (0.5 | %) | | |

| Change due to foreign exchange | | 0.2 | % | | | | | (2.2 | %) | | | | | (2.2 | %) | | | | | (0.2 | %) | | |

| Currency-neutral revenue growth (decline) | | 0.7 | % | | | | | (1.7 | %) | | | | | (1.7 | %) | | | | | (0.7 | %) | | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| Life Science segment revenue excluding process chromatography | | | | | | | | | | | | | | | |

| Revenue growth (decline), reported | | 2.0 | % | | | | | (6.0 | %) | | | | | 1.3 | % | | | | | (5.0 | %) | | |

| Change due to foreign exchange | | 0.5 | % | | | | | (1.8 | %) | | | | | (1.5 | %) | | | | | (0.4 | %) | | |

| Currency-neutral revenue growth (decline) | | 2.5 | % | | | | | (7.8 | %) | | | | | (0.2 | %) | | | | | (5.4 | %) | | |

| | | | | | | | | | | | | | | | |

Explanations of Non-GAAP Adjustments

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of amortization can vary significantly and are unique to each acquisition. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations.

Acquisition-related amounts: we incur expenses or benefits with respect to certain items associated with our acquisitions, including professional fees for assistance with the transaction; valuation costs, integration costs, changes in the fair value of contingent consideration, and gains and losses on the settlement of pre-existing relationships with the acquired entity. We exclude such acquisition-related amounts because they have no direct correlation to the operation of our on-going business.

Restructuring charges: we incur costs associated with our restructuring actions, including termination benefits related to reductions in employee headcount and the closure or exit of facilities. We exclude the costs associated with these unique restructuring actions in order to provide comparability of our on-going operations with prior and future periods.

Impairment charges: we incur non-cash expenses associated primarily with impairment of long-lived assets including, but not limited to, goodwill, intangible assets and property, plant and equipment. By excluding these impairment charges, we believe this assists investors with evaluating our cash spending and analyzing our core operating performance period-over-period.

Gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments: Our net income (loss) is impacted by gains and losses from change in fair market value of equity securities and loan receivable, and gain and losses associated with our equity-method investments included in Other income, net. These gains and losses arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. By excluding these gains and losses, we believe this assists investors in evaluating our core operating performance period-over-period.

Significant litigation amounts and legal costs: we may incur charges or benefits, in connection with litigation and other contingencies and legal costs unrelated to our core operations. We exclude these litigation amounts, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of our on-going business and operating results.

European Union’s IVDR: we incur incremental costs to comply with the European Union’s In Vitro Diagnostics Regulation (“IVDR”) for previously approved products.

Product portfolio rationalization related costs: we may incur charges associated with our product portfolio rationalization actions, including inventory write-downs, impairment of long-lived assets and accruals for contract termination or other exit-related costs. By excluding these one-time costs we believe this assists investors in evaluating our core operating performance period-over-period.

Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.

From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.

Other Key Metrics

Free Cash Flow: we report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for acquisitions and other investing and financing activities. The Company also uses this measure as an indication of the strength of the Company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

Currency-Neutral Revenue: we report percentage sales growth/decline in currency-neutral amounts by calculating translated prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales.

2026 Financial Outlook

Forecasted non-GAAP operating margin excludes 83 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities. We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments, future legal charges or benefits or future product portfolio rationalization related costs), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.

Investor Contact: Ruben Argueta, Investor Relations 510-741-6104 [email protected]

Media Contact: Anna Gralinska, Corporate Communications 510-741-6643 [email protected]

Source: Bio-Rad Laboratories, Inc.

View All News

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Bio-Rad Laboratories, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Bio-Rad Laboratories, Inc. to send you the requested Investor Email Alert updates.

  • Required

| Email Address * |

Investor Alert Options

| Investor Alert Options * |

| | News | | Quarterly Reports | | Annual Reports | | SEC Filings | | End of Day Stock Quote | | Events & Presentations | |

Submit Sign up

Unsubscribe

Email Alert Sign Up Confirmation

Investor Contact

Ruben Argueta Vice President, Investor Relations

phone icon 510-741-6104 mail icon [email protected]

Transfer Agent

Computershare PO Box 43078 Providence, RI 02940-3078

phone icon 800-962-4284 (within the U.S.) phone icon 781-575-3120 (outside the U.S.)

www.computershare.com

Bio-Rad logo

Follow us On

  • linkedin link youtube link facebook link instagram link

Company

Investor Contact

Ruben Argueta Vice President, Investor Relations

phone icon 510-741-6104 mail icon [email protected]

Transfer Agent

Computershare PO Box 43078 Providence, RI 02940-3078

phone icon 800-962-4284 (within the U.S.) phone icon 781-575-3120 (outside the U.S.)

www.computershare.com

Bio-Rad logo

Follow us On

  • linkedin link youtube link facebook link instagram link

Company

close disclaimer

Your Privacy Matters.

Before you visit, we want to let you know we use cookies and similar technologies for various purposes, including remembering your preferences, to offer you a better browsing experience. To learn more about how we use cookies and similar technologies, please review our Cookie Policy, accessible from the Manage Preferences link below. We would appreciate your confirmation by either accepting or by declining and managing your preferences.

Accept Decline Manage Preferences

close preference sidebar

Bio-Rad Cookie Preferences

Please use the following sections to learn more about the types of cookies we use, and how you can opt out of those you do not wish to be stored. At q4inc.com, we respect your privacy and are committed to protecting your information. For more information, you can review our Privacy Policy and Cookie Policy.

Accept Recommended Settings

Necessary Cookies

These cookies are necessary for the services and viewing experience of this site, and cannot be opted out of via this tool. If you still wish to remove these, you may do using your browser settings. A description of these technologies is provided in our Privacy Policy and Cookie Policy.

Adobe Analytics

adobeAnalytics option toggle on/off

We use analytics cookies and similar technologies to help ensure that your browsing experience is optimal. They collect anonymous data on how you use our website in order to build better, more useful pages. For instance, we can recognize and count the number of visitors, see how visitors moved around the site, and we can identify which pages returned error messages. This information enables us to enhance your experience and helps us troubleshoot any issues that prevented you from reaching the content that you needed. In order to improve the performance of our site, we use products such as Adobe Analytics to track site usage.

Analytical Cookies

googleAnalytics option toggle on/off

We would like to use Google Analytics to collect information about how visitors use our website. We use the information to compile reports and to help us improve the website. The cookies collect information including the number of visitors to the website and blog, where visitors have come to the website from and the pages they visited, but in a way that does not directly identify anyone (Anonymized IP).

Prompts

Bio-Rad Laboratories, Inc. (ticker BIO), listed in United States.

ETFs Holding Bio-Rad Laboratories, Inc.

ETF Weight in ETF Shares Market value As of
EPSB 1.70% 349 $ 127.86K Nov 13, 2026
EPMB 1.60% 207 $ 75.837K Nov 13, 2026
FEGE 1.22% 79,516 $ 30.703M Aug 31, 2026
FPAG 1.00% 18,472 $ 5.424M Jun 30, 2026
DFSV 0.55% 411,582 $ 152.483M Nov 12, 2026
SHRT 0.50% 181 $ 65.207K Nov 17, 2026
ITAN 0.36% 1,241 $ 444.514K Nov 17, 2026
HELX 0.26% 243 $ 71.347K Jun 30, 2026
MSSM 0.24% 4,465 $ 1.724M Aug 31, 2026
DFAS 0.16% 144,740 $ 53.623M Nov 12, 2026
GVLU 0.16% 1,192 $ 429.43K Nov 17, 2026
JMEE 0.10% 8,147 $ 2.918M Nov 17, 2026
AVMC 0.08% 1,193 $ 429.79K Nov 16, 2026
SFGV 0.08% 2,434 $ 870K Nov 18, 2026
FTLS short -0.06% -4,053 $ 0.00 Nov 16, 2026
DXUV 0.05% 8,072 $ 2.991M Nov 12, 2026
DFAT 0.04% 36,254 $ 13.431M Nov 12, 2026
DFAC 0.04% 86,617 $ 32.09M Nov 12, 2026
DFSU 0.03% 2,156 $ 798.755K Nov 12, 2026
DFUV 0.03% 12,848 $ 4.76M Nov 12, 2026
DCOR 0.03% 33,256 $ 12.321M Nov 12, 2026
AVSU 0.02% 208 $ 74.934K Nov 16, 2026
AVLC 0.02% 887 $ 319.551K Nov 16, 2026
DFAU 0.02% 5,293 $ 1.961M Nov 12, 2026
AVUS 0.01% 5,435 $ 1.958M Nov 16, 2026
DFUS 0.01% 5,652 $ 2.094M Nov 12, 2026
MSLC 0.01% 773 $ 298.471K Aug 31, 2026
EBI 0.00% 31 $ 11.97K Aug 31, 2026
NTRL short 0.00% -581 $ 0.00 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
BIO canonical Common share — US nyse 377.71 USD 2026-09-30
BIO-B Common share B US nyse 386.17 USD 2026-11-10